Surmodics, Inc. (SRDX)
NASDAQ: SRDX · Real-Time Price · USD
27.67
-0.47 (-1.67%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Surmodics Employees
Surmodics had 389 employees as of September 30, 2024. The number of employees increased by 13 or 3.46% compared to the previous year.
Employees
389
Change (1Y)
13
Growth (1Y)
3.46%
Revenue / Employee
$322,488
Profits / Employee
-$37,036
Market Cap
394.14M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novartis AG | 75,883 |
SRDX News
- 15 days ago - Surmodics Announces Commercial Release of Pounce™ XL Thrombectomy System, Enabling Rapid Non-Surgical Clot Removal in Iliac and Femoral Arteries - Business Wire
- 6 weeks ago - Surmodics Issues Statement on U.S. Federal Trade Commission Challenge to Proposed Acquisition of Surmodics by Funds Affiliated with GTCR - Business Wire
- 6 weeks ago - FTC sues to block private equity firm's deal to buy medical device coatings maker Surmodics - Reuters
- 2 months ago - Top 3 Health Care Stocks You'll Regret Missing This Month - Benzinga
- 2 months ago - Surmodics Announces Successful Early Clinical Use of Pounce™ XL Thrombectomy System, Suitable for Non-Surgical Removal of Thrombi and Emboli from Iliac and Femoral Arteries - Business Wire
- 2 months ago - Surmodics Reports First Quarter of Fiscal Year 2025 Financial Results - Business Wire
- 5 months ago - Surmodics Reports Fourth Quarter and Fiscal Year 2024 Financial Results - Business Wire
- 6 months ago - Surmodics Announces Early Results from PROWL Registry Study of Real-World Limb Ischemia Patients Treated with Pounce™ Thrombectomy System - Business Wire